Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Pursue Wealth Partners LLC

Pursue Wealth Partners LLC lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 14.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 13,700 shares of the biotechnology company’s stock after selling 2,300 shares during the period. Pursue Wealth Partners LLC’s holdings in Exelixis were worth $329,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. American Century Companies Inc. increased its holdings in Exelixis by 31.5% in the 3rd quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company’s stock valued at $30,811,000 after purchasing an additional 338,021 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in Exelixis by 236.3% in the 4th quarter. State of Alaska Department of Revenue now owns 127,287 shares of the biotechnology company’s stock valued at $3,053,000 after purchasing an additional 89,436 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Exelixis by 244.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company’s stock valued at $2,839,000 after purchasing an additional 83,999 shares during the last quarter. Advisors Preferred LLC acquired a new stake in Exelixis in the 4th quarter valued at approximately $3,384,000. Finally, Seven Eight Capital LP increased its holdings in Exelixis by 61.7% in the 3rd quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 8,305 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Up 0.7 %

Shares of Exelixis stock traded up $0.17 on Friday, reaching $23.70. 1,560,811 shares of the stock were exchanged, compared to its average volume of 1,843,234. Exelixis, Inc. has a 1-year low of $18.08 and a 1-year high of $24.34. The business has a fifty day moving average price of $22.80 and a two-hundred day moving average price of $22.19. The firm has a market capitalization of $6.99 billion, a PE ratio of 37.03, a PEG ratio of 0.61 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The business had revenue of $479.65 million for the quarter, compared to analyst estimates of $481.23 million. Research analysts expect that Exelixis, Inc. will post 1.23 EPS for the current year.

Insider Transactions at Exelixis

In related news, Director David Edward Johnson bought 190,000 shares of the stock in a transaction on Wednesday, February 21st. The shares were bought at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the transaction, the director now owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Patrick J. Haley sold 47,020 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the completion of the transaction, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at approximately $8,255,375.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David Edward Johnson acquired 190,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the purchase, the director now owns 1,100,730 shares in the company, valued at $22,785,111. The disclosure for this purchase can be found here. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus boosted their price target on shares of Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. JMP Securities reissued a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research report on Wednesday, April 10th. Barclays cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target for the company. in a research report on Thursday, April 11th. Finally, William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.